- Login
- Register & Subscribe
- Language: EN FR DE
Clinical Research
Scancell gives early data on cancer vaccine
Friday 7 December 2012
Another potential therapy for patients with melanoma has emerged with the disclosure on 6 December of preliminary results of a therapeutic cancer vaccine in which four patients showed an immune response. The vaccine has been developed by Scancell Holdings Plc.
Location
United Kingdom
TxCell gets funding for cell therapy
Tuesday 27 November 2012
TxCell SA of France, which is developing cell-based immunotherapies for chronic inflammatory diseases, has raised €12.4 million from existing shareholders and a new investor to finance a proof-of-concept study of its lead product for Crohn’s disease.
Location
France
Pharming receives $10 million milestone
Monday 26 November 2012
Pharming Group NV has received a $10 million milestone payment from its partner Santarus Inc following the successful Phase 3 trial of Ruconest, its lead drug for hereditary angioedema (HAE). The trial result was reported on 7 November.
Location
Netherlands
CureVac vaccines said to protect against flu
Sunday 25 November 2012
A new vaccine technology based on messenger RNA is reported to be effective in animals with influenza A. Data from the studies has been published online in Nature Biotechnology. The vaccines were developed by CureVac GmbH.
Location
Germany
Phase 3 trial to start for cell therapy for heart disease
Friday 23 November 2012
The Belgian drug regulator has approved the start of a Phase 3 trial of an autologous cell therapy for patients with chronic heart failure – understood to be the first such trial ever. The therapy was developed by Cardio3 BioSciences SA and the US Mayo Clinic.
Location
Belgium
Medivir gives update on simeprevir
Thursday 22 November 2012
Medivir AB of Sweden expects to start a Phase 2 study early next year of a new combination treatment for hepatitis C, as part of its ongoing efforts to build a franchise around its protease inhibitor, simeprevir (TMC435).
Location
Sweden
Oxford BioMedica gives ocular update
Tuesday 20 November 2012
Oxford BioMedica Plc has given a clinical update on its gene therapy programmes for ocular diseases, highlighting the safety of its early-stage therapy for a subtype of the deaf-blindness disorder, Usher syndrome. Sanofi SA has in-licensed the programme.
Location
United Kingdom
Algeta prepares regulatory filing
Friday 16 November 2012
Algeta ASA said it is on course to complete a US regulatory filing for the radium-223 product, Alpharadin, for advanced prostate cancer patients with bone metastases by the end of 2012. The drug is partnered with Bayer Pharma AG.
Location
Norway
Mologen to test immunotherapy in lung cancer
Thursday 15 November 2012
Mologen AG has confirmed plans to start a Phase 2 study of its lead compound, MGN1703, in non-small cell lung cancer having shown evidence earlier this year of improved progression free survival of the same drug in colorectal cancer.
Location
Germany
Clavis suspends work on pancreatic cancer drug
Wednesday 14 November 2012
Clavis Pharma ASA has suspended all work on a lipid-based drug for pancreatic cancer following the drug’s failure in a pivotal trial. The trial was being conducted by Clavis’s partner, Clovis Oncology Inc.
Location
Norway
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013